Medical Dosimetry
Volume 33, Issue 3 , Pages 180-190 , Autumn 2008

Feasibility of IMRT to Cover Pelvic Nodes While Escalating the Dose to the Prostate Gland: Dosimetric Data on 35 Consecutive Patients

  • John E. Bayouth, Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Iowa Health Care, Iowa City, IA
    • Corresponding Author InformationReprint requests to: John E. Bayouth, Ph.D., Department of Radiation Oncology, University of Iowa Health Care, 200 Hawkins Drive, Iowa City, IA 52242.
    • ,
  • John Pena, M.S.

      Affiliations

    • Department of Medical Physics, University of Texas Medical Branch, Galveston, TX
    • ,
  • Laura Culp, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX
    • ,
  • Collin Brack, M.B.A.

      Affiliations

    • Department of Medical Physics, University of Texas Medical Branch, Galveston, TX
    • ,
  • Giuseppe Sanguineti, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX

Received 24 January 2007 ,Accepted 26 May 2007.

References 

  1. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet. 2002;360:103–106
  2. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 2005;61:1285–1290
  3. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J. Clin. Oncol. 2000;18:3904–3911
  4. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J. Clin. Oncol. 2003;21:1904–1911
  5. Sanguineti G, Agostinelli S, Foppiano F, et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br. J. Cancer. 2002;86:1843–1847
  6. Feigenberg SJ, Hanlon AL, Horwitz EM, et al. Androgen deprivation increases late morbidity in prostate cancer patients treated with 3D conformal radiation therapy. (abstract) Int. J. Radiat. Oncol. Biol. Phys. 2003;57:S176
  7. Michalski JM, Winter K, Purdy JA. Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level V (abstract). Int. J. Radiat. Oncol. Biol. Phys. 2003;57:S151
  8. Kuban D, Pollack A, Huang E, et al. Hazards of dose escalation in prostate cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2003;57:1260–1268
  9. Jacob R, Hanlon AL, Horwitz EM, et al. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int. J. Radiat. Oncol. Biol. Phys. 2005;61:695–701
  10. Cavey, M.L.; Bayouth, J.E.; Colman, M. Is dose escalation to the prostate feasible while treating the pelvic nodes with IMRT? Presented at the XIV International Conference on the Use of Computers in Radiation Therapy, May 10–13, 2004, Seoul, Korea.
  11. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003;57:953–962
  12. Rosen E, Cassady JR, Connolly J, et al. Radiotherapy for prostate carcinoma: The JCRT experience (1968–1978) (II. Factors related to tumor control and complications). Int. J. Radiat. Oncol. Biol. Phys. 1985;11:723–730
  13. Perez CA, Lee HK, Georgiou A, et al. Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 1994;28:811–819
  14. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int. J. Radiat. Oncol. Biol. Phys. 2002;53:1111–1116
  15. Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2000;48:649–656
  16. Woo S, Kaplan I, Roach M, et al. Formula to estimate risk of pelvic lymph node metastasis from the total Gleason score for prostate cancer. J. Urol. 1988;140:387
  17. Radiation Therapy Oncology Group (RTOG). 99-10: A phase III trial to evaluate the duration of neoadjuvant total androgen suppression (TAS) and radiation therapy (RT) in intermediate risk prostate cancer, opened 1999. Available at: www.rtog.org/.
  18. Ezzell GA, Galvin JM, Low D, et al. Guidance document on delivery, treatment planning, and clinical implementation of IMRT: Report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med. Phys. 2003;30:2089–2115
  19. Fiorino C, Cozzarini C, Vavassori V, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: Analysis of a large group of patients pooled from three institutions. Radiother. Oncol. 2002;64:1–12
  20. Malone S, Donker R, Broader M, et al. Effects of urethrography on prostate position: Considerations for radiotherapy treatment planning of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2000;46:89–93
  21. Colman M, Bayouth JE, Reddy MA, et al. A simplified approach to forward planning IMRT. (abstract) Radiother. Oncol. 2001;58:S22
  22. International Commission on Radiation Units and Measurement (ICRU). Report No. 50: Prescribing, Recording and Reporting Photon Beam Therapy. Washington, D.C: ICRU; 1993;
  23. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: Current status and issues of interest. Int. J. Radiat. Oncol. Biol. Phys. 2001;51:880–914
  24. Radiation Therapy Oncology Group (RTOG). RTOG-0126: A phase III randomized study of high dose 3D-CRT versus standard dose 3D-CRT in patients treated for localized prostate cancer, opened 2000. Available at: www.rtog.org/.
  25. Radiation Therapy Oncology Group (RTOG). H-0225: A phase II study of intensity modulated radiation therapy (IMRT) +/− chemotherapy for nasopharyngeal cancer, opened 2000. Available at: www.rtog.org/.
  26. Radiation Therapy Oncology Group (RTOG). H-0022: A phase I/II study of conformal and intensity modulated irradiation for oropharyngeal cancer, opened 2000. Available at: www.rtog.org/.
  27. Huan EH, Pollack A, Levy L, et al. Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002;54:1314–1321
  28. Siochi RA. Minimizing static intensity modulation delivery time using an intensity solid paradigm. Int. J. Radiat. Oncol. Biol. Phys. 1999;43:671–680
  29. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 1995;31:1341–1346
  30. Sanguineti G, Culp L, Pena J, et al. Acute small bowel and colon toxicity after pelvic IMRT for prostate cancer (abstract). Eur. J. Cancer. 2003;1:S268
  31. Sanguineti G, Franzone P, Marcenaro M, et al. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma (A randomized study). Strahlenther. Onkol. 2003;179:464–470
  32. Portelance L, Chao KS, Grigsby PW, et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2001;51:261–266
  33. Roeske JC, Lujan A, Rotmensch J, et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 2000;48:1613–1621
  34. Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 2002;52:1330–1337
  35. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2003;56:1354–1360
  36. Mund AJ, Roeske JC, Lujan AE, et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol. Oncol. 2001;82:456–463
  37. Koper PC, Stroom JC, van Putten WL, et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: A randomized study. Int. J. Radiat. Oncol. Biol. Phys. 1999;43:727–734
  38. Hovdenak N, Karlsdottir A, Sorbye H, et al. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncol. 2003;42:741–748
  39. O'Brien PC, Franklin CI, Dear KB, et al. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. Radiother. Oncol. 1997;45:117–123
  40. Michalski JM, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int. J. Radiat. Oncol. Biol. Phys. 2000;46:391–402
  41. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int. J. Radiat. Oncol. Biol. Phys. 2002;54:1036–1046
  42. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2000;48:635–642
  43. Xia P, Pickett B, Vigneault E, et al. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int. J. Radiat. Oncol. Biol. Phys. 2001;51:244–254
  44. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int. J. Radiat. Oncol. Biol. Phys. 2005;61:1019–1034
  45. Roach M, Winter K, Michalski JM. Mean dose of radiation to the bulb of the penis correlates with risk of erectile dysfunction at 24 months: Preliminary analysis of Radiation Therapy Oncology Group (RTOG) phase I/II dose escalation trial 94-06. (abstract) Int. J. Radiat. Oncol. Biol. Phys. 2000;48:316
  46. Blute ML, Bostwick DG, Bergstralh EJ, et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997;50:733–739
  47. Thwaites D, Scalliet P, Leer JW, et al. Quality ssurance in radiotherapy (European Society for Therapeutic Radiology and Oncology Advisory Report to the Commission of the European Union for the “Europe Against Cancer Programme”). Radiother. Oncol. 1995;35:61–73
  48. Bortfeld. T.; Thieke, C.; Kufer, K.H.; et al. New Approaches in Intensity Modulated Radiotherapy. Presented at the ICRO/OGRO Meeting, May 15–19, 2002, Salzburg, Austria.

PII: S0958-3947(07)00111-2

doi: 10.1016/j.meddos.2007.05.006

Medical Dosimetry
Volume 33, Issue 3 , Pages 180-190 , Autumn 2008

Article Tools

* Image Usage & Resolution